### Wednesday, 26 March 2014

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:15</td>
<td>INDUSTRY SATELLITE SYMPOSIUM</td>
<td>ROOM C</td>
</tr>
<tr>
<td>13:15</td>
<td><strong>Up close and personal: future targeted strategies in NSCLC</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>See page 60 for details</td>
<td></td>
</tr>
<tr>
<td>13:15</td>
<td>WELCOME RECEPTION</td>
<td>EXHIBITION</td>
</tr>
<tr>
<td>13:45</td>
<td>OPENING AND WELCOME</td>
<td>ROOM A&amp;B</td>
</tr>
<tr>
<td>13:45</td>
<td>Welcome to the Conference</td>
<td></td>
</tr>
<tr>
<td>13:50</td>
<td>Introduction to ESMO</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rolf A. Stahel, Zurich, Switzerland</td>
<td></td>
</tr>
<tr>
<td>13:55</td>
<td>Introduction to IASLC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tony S.K. Mok, Hong Kong, China</td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td>KEYNOTE LECTURE</td>
<td>ROOM A&amp;B</td>
</tr>
<tr>
<td>14:30</td>
<td><strong>Immunomodulation, with a focus on clinical development PD1 and anti-PD1</strong></td>
<td>ROOM A&amp;B</td>
</tr>
<tr>
<td></td>
<td>Chairs: Enriqueta Felip, Barcelona, Spain and Rafał Dziadziośzko, Gdansk, Poland</td>
<td>ROOM A&amp;B</td>
</tr>
<tr>
<td>14:00</td>
<td>Speaker: Julie Brahmer, Baltimore, MD, US</td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td>EDUCATIONAL SESSION</td>
<td>ROOM A&amp;B</td>
</tr>
<tr>
<td>16:00</td>
<td><strong>The epidemiology of lung cancer</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: Paolo Boffetta, Lyon, France and to be announced</td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td>Demographic changes</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Paolo Boffetta, Lyon, France</td>
<td></td>
</tr>
<tr>
<td>14:50</td>
<td>Molecular epidemiology of lung cancer and geographic variations</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tetsuya Mitsudomi, Osaka-Sayama, Japan</td>
<td></td>
</tr>
<tr>
<td>15:10</td>
<td>The impact of measures against tobacco</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Peter Boyle, Lyon, France</td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td>Smoking cessation as part of cancer therapy: Does it really impact outcome?</td>
<td>EXHIBITION</td>
</tr>
<tr>
<td></td>
<td>Virginie Westeel, Besancon, France</td>
<td></td>
</tr>
<tr>
<td>15:50</td>
<td>Questions and answers</td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td>COFFEE BREAK</td>
<td>EXHIBITION</td>
</tr>
</tbody>
</table>
16:30/ 18:00  EDUCATIONAL SESSION
Biomarkers in lung cancer
Chairs: David Gandara, Sacramento, CA, US and to be announced

16:30  Prognostic markers: Ready for prime-time?
Ming Tsao, Toronto, ON, Canada

16:55  How to implement predictive markers in clinical trials
David Gandara, Sacramento, CA, US

17:20  Potential biomarkers for screening
Gabriella Sozzi, Milan, Italy

17:45  Questions and answers

18:30/  19:30  INDUSTRY SATELLITE SYMPOSIUM
Immuno-Oncology: The new horizon in lung cancer
See page 60 for details

Thursday, 27 March 2014

08:00/ 08:50  MULTIDISCIPLINARY INTERACTIVE SESSION
Systemic treatment in EGFR/ALK - NSCLC patients
Chairs: Rafael Rosell, Badalona, Spain and Mark Socinski, Pittsburgh, PA, US

08:00  First line
Mark Socinski, Pittsburgh, PA, US

08:15  Second line and beyond
Rafael Rosell, Badalona, Spain

08:30  Discussion

08:00/ 08:50  YOUNG ONCOLOGISTS SESSION
Evolution of the treatment paradigm for advanced non small cell lung cancer
Chairs: Raffaele Califano, Manchester, UK and Federico Cappuzzo, Livorno, Italy

08:00  Non-small cell lung cancer: From ugly duckling to fascinating disease
Raffaele Califano, Manchester, UK

08:20  Challenges in the design of the next generation of clinical trials for advanced NSCLC
Federico Cappuzzo, Livorno, Italy

08:40  Discussion

08:00/ 08:50  MULTIDISCIPLINARY INTERACTIVE SESSION
Loco-regional treatment for single station N2 NSCLC
Chairs: Jan Van Meerbeeck, Edegem, Belgium and David Waller, Leicester, UK
08:00 Radiotherapy
Jan Van Meerbeeck, Edegem, Belgium

08:15 Surgery
David Waller, Leicester, UK

08:30 Discussion

08:00/08:50 MULTIDISCIPLINARY INTERACTIVE SESSION
ROOM V

08:50 Thymoma
Chairs: Giuseppe Giaccone, Washington, DC, US and Witold Rzyman, Gdansk, Poland

08:00 Systemic therapy
Giuseppe Giaccone, Washington, DC, US

08:15 Thoracic surgery
Witold Rzyman, Gdansk, Poland

08:30 Discussion

09:00/10:30 PROFFERED PAPERS SESSION
ROOM A&B

10:30 Advanced disease with targeted agents
Chairs: Solange Peters, Lausanne, Switzerland and to be announced

09:00 91O - Quality of life (QoL) analysis from ENSURE, a phase 3, open-label study of first-line erlotinib versus gemcitabine/cisplatin (GP) in Asian patients with epidermal growth factor receptor (EGFR) mutation-positive (mut+) non-small-cell lung cancer (NSCLC)
Yi-Long Wu, Guangzhou, China

09:15 92O - Tumor burden and tyrosine kinase inhibitors (TKI) benefit in advanced non-small cell lung cancer (NSCLC) patients with EGFR sensitizing mutations (EGFRm) and ALK rearrangement (ALK+)
Charlotte Leduc, Strasbourg, France

09:30 93O - First-In-Human Evaluation of CO-1686, an Irreversible, Highly Selective Tyrosine Kinase Inhibitor of Mutations of EGFR (Activating and T790M)
Heather Wakelee, Stanford, CA, US

09:45 Discussant abstracts 91O, 92O and 93O
Tony S. K. Mok, Hong Kong, China

10:00 94O - Lung adenocarcinoma with RET fusion: Early experience with diagnosis and targeted therapy
Oliver Gautschi, Lucerne, Switzerland

10:15 Discussant abstract 94O
Mark Kris, New York, NY, US

09:00/10:30 SPECIALTY SESSION
ROOM X

10:30 Pathology
Chairs: Elisabeth Brambilla, Grenoble, France and Keith Kerr, Aberdeen, UK
09:00 Alignment of lung cancer histology and molecular drivers
Roman Thomas, Cologne, Germany
09:20 Gene expression and epigenetics in lung cancer
Ming Tsao, Toronto, ON, Canada
09:40 Genetic heterogeneity in lung cancer
Keith Kerr, Aberdeen, UK
10:00 Molecular features of pre-invasive lung lesions and value for early detection and prevention
Ignacio Wistuba, Houston, TX, US
10:20 Discussion

09:15/10:15 CONTROVERSY SESSION
ROOM C
10:15 Surgery vs stereotactic body radiation therapy (SBRT) in operable NSCLC patients
Chairs: Suresh Senan, Amsterdam, Netherlands and Walter Weder, Zurich, Switzerland
09:15 Introduction and first vote
09:25 SABR in operable cases: Where is the evidence?
Matthias Guckenberger, Würzburg, Germany
09:45 Modern concepts and results of surgery for early stage NSCLC
Pascal A. Thomas, Marseille, France
10:05 Second vote and conclusions
10:30 COFFEE BREAK

11:00/12:30 PROFFERED PAPERS SESSION
ROOM A&B
11:00 10 - Detection of ALK rearranged non-small cell lung carcinomas by immunohistochemistry: Comparison of different antibodies (D5F3 and 5A4), detection systems and automated immunostainers
Spasenija Savic, Basel, Switzerland
11:15 20 - Significance of lepidic growth component in the discrimination of multiple primary lung cancers from intrapulmonary metastases
Dongmei Lin, Beijing, China
11:30 Discussant abstracts 10 and 20
Tetsuya Mitsudomi, Osaka-Sayama, Japan
11:45 380 - PD-L1 and PD-1 expression in molecularly selected non-small-cell lung cancer (NSCLC) patients
Armida D’Incecco, Livorno, Italy
12:00 1270 - Programmed cell death 1 ligand 1 expression and association with survival in mesothelioma
Aaron Mansfield, Rochester, MN, US
Check out the programme, find exhibitors, organise your agenda and more. Download it now on the iTunes and Android stores.
12:15 Discussant abstracts 380 and 1270
Fred Hirsch, Aurora, CO, US

11:00/ 12:30 EDUCATIONAL SESSION
ROOM C
12:30 Early drug development of targeted therapies in NSCLC
Chairs: Tony S.K. Mok, Hong Kong, China and Frances Shepherd, Toronto, ON, Canada

11:00 Preclinical testing: Animal models, clinical models
Pasi Jänne, Boston, MA, US

11:20 Early phase I trials
Sophie Postel-Vinay, Villejuif, France

11:40 Late drug-development
Tony S.K. Mok, Hong Kong, China

12:00 Challenges of collaboration between academia and pharma
Thierry Le Chevalier, Villejuif, France

12:20 Questions and answers

11:00/ 12:30 SPECIALTY SESSION
ROOM X
12:30 Radiotherapy
Chairs: Rafal Dziadzioiusko, Gdansk, Poland and Dirk de Ruysscher, Leuven, Belgium

11:00 IGRT: Technical challenges and role in SBRT and particle therapy
Matthias Gluckenberger, Würzburg, Germany

11:22 Optimal radiotherapy for stage III NSCLC in 2014: What dose/fractionation for concurrent and sequential schedules?
Dirk de Ruysscher, Leuven, Belgium

11:44 SBRT for lung cancer: Going beyond small inoperable NSCLC
Krzysztof Konopa, Gdansk, Poland

12:06 Safety of SBRT: What are current tolerance doses according to different fractionation schedules?
Ursula Nestle, Freiburg, Germany

12:30 LUNCH & POSTER DISPLAY SESSION
See page 40 for details

13:10/ 14:20 INDUSTRY SATELLITE SYMPOSIUM
ROOM C
14:20 Targeting the consequences of bone metastases in lung cancer
See page 61 for details
14:30/ 16:00 EDUCATIONAL SESSION
Local therapies in oncogenic-driven diseases
Chairs: Françoise Mornex, Lyon, France and Pilar Garrido, Madrid, Spain

14:30 Brain metastases
Rafal Dziadziuszko, Gdansk, Poland

14:50 The place of targeted agents in multimodality treatment of stage III
Solange Peters, Lausanne, Switzerland

15:10 Local treatment for residual disease
Helena Yu, New York, NY, US

15:30 The management of oligo-progression disease
Mark Kris, New York, NY, US

15:50 Questions and answers

14:30/ 16:00 SPECILATY SESSION
Surgery
Chairs: Paul Van Schil, Edegem, Belgium and Eric Vallieres, Seattle, WA, US

14:30 Introduction
Paul Van Schil, Edegem, Belgium

14:35 Preoperative mediastinal lymph node staging of lung cancer: Update to ESTS guidelines
Paul De Leyn, Leuven, Belgium

14:55 Sublobar resection for early-stage lung cancer
Hisao Asamura, Tokyo, Japan

15:15 Lung cancer R0 resection: Robot, VATS or muscle-sparing thoracotomy?
Eric Vallieres, Seattle, WA, US

15:35 Questions and answers / Panel discussion

14:30/ 15:30 POSTER DISCUSSION 1
Chairs: Lukas Bubendorf, Basel, Switzerland and Mark Ladanyi, New York, NY, US

74PD - When is a pathological diagnosis preferred before Stereotactic Ablative Radiotherapy (SABR) for stage I lung cancer? A decision analysis
Alexander Louie, Amsterdam, Netherlands

82PD - European Harmonization Study for the immunohistochemical detection of ALK-rearranged NSCLC (on behalf of all 16 participating institutes enrolled in the study)
Maximilian von Laffert, Berlin, Germany

3PD - ALK and MET are synergistic co-activators of downstream signals by amplification in pulmonary sarcomatoid carcinoma: A potential for targeted therapy?
Patrizia Gasparini, Milan, Italy
4PD - The prognostic effect of IASLC/ATS/ERS classification of lung adenocarcinoma on postrecurrence survival in resected adenocarcinoma
Jung-Jyh Hung, Taipei, Taiwan

14:30 Discussant abstracts 74PD, 82PD, 3PD and 4PD
Lukas Bubendorf, Basel, Switzerland

26PD - An innovative technology for in vivo isolation of circulating tumor cells in non-small cell lung cancer (NSCLC) patients and immunofluorescent detection of ALK protein
Barbara Dlugaszewska, Potsdam, Germany

39PD - Ultra-deep sequencing of circulating free DNA to identify predictive, mutated HSP90 clients in GALAXY-1 (NCT01348126), a randomized phase 2b study of ganetespib plus docetaxel versus docetaxel alone in 2nd line advanced NSCLC
Dean Fennell, Leicester, UK

95PD - Molecular heterogeneity and response to Gefitinib of EGFR mutant advanced lung adenocarcinoma
Silvia Novello, Orbassano, Italy

14:50 Discussant abstracts 26PD, 39PD and 95PD
Mark Ladanyi, New York, NY, US

15:10 General discussion

16:00 COFFEE BREAK

16:30/18:00 EDUCATIONAL SESSION

18:00 Mesothelioma: Standards and controversies
Chairs: Marc Ladanyi, New York, NY, US and Dominique Grunenwald, Paris, France

16:30 Molecular biology of mesothelioma: Implications for the development of new targeted therapies
Marc Ladanyi, New York, NY, US

16:55 EPP versus pleurectomy/decortication in early mesothelioma
Loic Lang-Lazdunski, London, UK

17:20 Development of systemic treatment
Dean Fennell, Leicester, UK

17:45 Questions and answers

16:30/18:00 EDUCATIONAL SESSION

18:00 Pathology: The new WHO classification proposal changes
Chairs: Elisabeth Brambilla, Besancon, France and Keith Kerr, Aberdeen, UK

16:30 Adenocarcinoma classification and its potential clinical impact
Andrew Nicholson, London, UK
16:55 Squamous-cell carcinomas and large-cell carcinomas
Ignacio Wistuba, Houston, TX, US

17:20 Neuroendocrine tumours of the lung
Elisabeth Brambilla, Besancon, France

17:45 Questions and answers

16:30/18:00 SPECIALTY SESSION
18:00 Targeted therapies in NSCLC
Chairs: Solange Peters, Lausanne, Switzerland and Martin Reck, Grosshansdorf, Germany

16:30 Targeting ALK and facing ALK TKI resistance
Alice Shaw, Boston, MA, US

17:00 EGFR blockade: Is there anything new?
Caciun Zhou, Shanghai, China

17:30 The challenge of new target pathways
Alex A. Adjei, Buffalo, NY, US

18:20/19:20 INDUSTRY SATELLITE SYMPOSIUM
19:20 An evolving landscape: Clinical implications for NSCLC treatment
See page 61 for details

18:20/19:20 INDUSTRY SATELLITE SYMPOSIUM
19:20 Improving management of advanced non-small cell lung cancer
See page 61 for details

Friday, 28 March 2014

08:00/08:50 MULTIDISCIPLINARY INTERACTIVE SESSION
08:00 Next generation sequencing for molecular sub-typing
Chairs: Fred Hirsch, Aurora, CO, US and Antonio Marchetti, Chieti, Italy

08:00 How to integrate sequencing strategies with other techniques
Fred Hirsch, Aurora, CO, US

08:15 Sequencing and multiplex platforms: What should we use for our patients?
Antonio Marchetti, Chieti, Italy

08:30 Discussion

08:00/08:50 YOUNG ONCOLOGISTS SESSION II
08:00 Challenges in maintenance treatment in advanced NSCLC
Chairs: Jesus Corral, Seville, Spain and Giannis Mountzios, Athens, Greece
08:00 Chemotherapeutic or targeted agents as maintenance treatment: Efficacy and toxicity issues
Jesus Corral, Seville, Spain

08:20 Do benefits outweigh the costs?
Giannis Mountzios, Athens, Greece

08:40 Discussion

08:00/08:50 MULTIDISCIPLINARY INTERACTIVE SESSION
ROOM W
08:50 Sexuality and cancer
Chairs: Stéphan Droupy, Nîmes, France and Luca Incrocci, Rotterdam, Netherlands

08:00 How to evaluate sexual dysfunction
Luca Incrocci, Rotterdam, Netherlands

08:15 Symptomatic treatment for sexual side effects
Stéphan Droupy, Nîmes, France

08:30 Discussion

08:00/08:50 MULTIDISCIPLINARY INTERACTIVE SESSION
ROOM V
08:50 Management of carcinoid tumours
Chairs: Eric Baudin, Villejuif, France and Eric Lim, London, UK

08:00 Surgery
Eric Lim, London, UK

08:15 Systemic treatment
Eric Baudin, Villejuif, France

08:30 Discussion

09:00/10:30 EDUCATIONAL SESSION
ROOM A&B
10:30 Neuroendocrine lung tumours / SCLC
Chairs: Birgit Guldhammer Skov, Copenhagen, Denmark and Corinne Faivre-Finn, Manchester, UK

09:00 Advances in molecular biology of SCLC
John Poirier, New York, NY, US

09:20 Optimisation of radiotherapy in small cell lung cancer
Corinne Faivre-Finn, Manchester, UK

09:40 Systemic treatment
Mary O’Brien, Sutton, UK

10:00 Surgery: Does it have a place?
Walter Klepetko, Vienna, Austria

10:20 Questions and answers

09:00/10:30 PROFFERED PAPERS SESSION
ROOM X
10:30 Screening, staging and epidemiology
Chairs: Tetsuya Mitsudomi, Osaka-Sayama, Japan and to be announced
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Authors/Institutions</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00</td>
<td><strong>24O</strong> - Clinical Utility of a Plasma-based microRNA Signature Classifier within Computed Tomography Lung Cancer Screening</td>
<td><em>Ugo Pastorino, Milan, Italy</em></td>
</tr>
<tr>
<td>09:15</td>
<td>Discussant abstract 240</td>
<td><em>Johan Vansteenkiste, Leuven, Belgium</em></td>
</tr>
<tr>
<td>09:30</td>
<td><strong>25O</strong> - International comparison of treatment and survival for pleural mesothelioma, combined analysis of 9,014 patients from Belgium, the Netherlands and England</td>
<td><em>Jan Van Meerbeeck, Edegem, Belgium</em></td>
</tr>
<tr>
<td>09:45</td>
<td>Discussant abstract 250</td>
<td><em>Paul Baas, Amsterdam, Netherlands</em></td>
</tr>
<tr>
<td>10:00</td>
<td><strong>59O</strong> - Alternative methods of PET-CT interpretation: Can we improve mediastinal nodal staging in lung cancer patients?</td>
<td><em>Matthew Evison, Manchester, UK</em></td>
</tr>
<tr>
<td>10:15</td>
<td>Discussant abstract 590</td>
<td><em>Christophe Dooms, Leuven, Belgium</em></td>
</tr>
<tr>
<td>09:15</td>
<td>CONTROVERSY SESSION</td>
<td>ROOM C</td>
</tr>
<tr>
<td>10:15</td>
<td>EGFR-TKI with CT: Combined or sequential in EGFR-mutant patients?</td>
<td>Chairs: <em>Tony S.K. Mok, Hong Kong, China and Federico Cappuzzo, Livorno, Italy</em></td>
</tr>
<tr>
<td>09:15</td>
<td>Introduction and first vote</td>
<td>ROOM A&amp;B</td>
</tr>
<tr>
<td>09:25</td>
<td>Sequential combination</td>
<td><em>Yi Long Wu, Guangzhou, China</em></td>
</tr>
<tr>
<td>09:45</td>
<td>Combined</td>
<td><em>Luis Paz-Ares, Seville, Spain</em></td>
</tr>
<tr>
<td>10:05</td>
<td>Second vote and conclusions</td>
<td>ROOM C</td>
</tr>
<tr>
<td>10:30</td>
<td>COFFEE BREAK</td>
<td>EXHIBITION</td>
</tr>
<tr>
<td>11:00</td>
<td>EDUCATIONAL SESSION</td>
<td>ROOM A&amp;B</td>
</tr>
<tr>
<td>12:30</td>
<td>Overcoming resistance in oncogenic-driven disease</td>
<td>Chairs: <em>Egbert Smit, Amsterdam, Netherlands and Cesare Gridelli, Avellino, Italy</em></td>
</tr>
<tr>
<td>11:00</td>
<td>Resistance mechanisms to first and second generation EGFR inhibitors</td>
<td><em>Keunchil Park, Seoul, Korea</em></td>
</tr>
<tr>
<td>11:25</td>
<td>Resistance mechanisms to ALK/ROS1 inhibitors</td>
<td><em>Robert Doebele, Aurora, CO, US</em></td>
</tr>
<tr>
<td>11:50</td>
<td>BRAF, HER2</td>
<td><em>Benjamin Besse, Villejuif, France</em></td>
</tr>
<tr>
<td>12:15</td>
<td>Questions and answers</td>
<td>ROOM C</td>
</tr>
<tr>
<td>11:00</td>
<td>PROFFERED PAPERS SESSION</td>
<td>ROOM C</td>
</tr>
<tr>
<td>12:30</td>
<td>SCLC and locally advanced NSCLC</td>
<td>Chairs: <em>David Gandara, Sacramento, CA, US and Mary O’Brien, Sutton, UK</em></td>
</tr>
</tbody>
</table>
11:00 800 - Determinants of survival in 7,214 patients with stage III NSCLC treated with chemoradiotherapy in the Netherlands
Jose Belderbos, Amsterdam, Netherlands

11:12 810 - Potentially Functional Single Nucleotide Polymorphisms in CD133 Predict Local Recurrence and Distant Metastasis after Radiotherapy for Non-Small Cell Lung Cancer
Qiming Wang, Zhengzhou, China

11:24 1240 - Stereotactic ablative body radiotherapy (SABR) with flattening filter free (FFF) mode for NSCLC oligometastatic patients: feasibility and outcomes
Pierina Navarria, Rozzano, Italy

11:36 Discussant abstracts 800, 810 and 1240
Francoise Mornex, Lyon, France

11:51 660 - Outcomes of platinum-sensitive Small Cell Lung Cancer (SCLC) patients treated with platinum-based chemotherapy rechallenge: a multi-institutional retrospective analysis
Raffaele Califano, Manchester, UK

12:03 670 - Cabazitaxel (Cbz) vs topotecan (Tpt) in patients (pts) with small cell lung cancer (SCLC) with progressive disease during/after first-line (1L) treatment with platinum-based chemotherapy (ctx)
Tracey Evans, Philadelphia, PA, US

12:15 Discussant abstracts 660 and 670
Pilar Garrido, Madrid, Spain

11:00/12:30 SPECIAL SESSION – ESO
12:30 The 1st ESO Lung Cancer Observatory: Innovation and care in the next 12 months
Chair: Enriqueta Felip, Barcelona, Spain
Moderator: Matti Aapro, Geneva, Switzerland

Surgery & screening
Ugo Pastorino, Milan, Italy

Progress in radiation oncology
Dirk De Ruysscher, Leuven, Belgium

Translational research
To be announced

Progress in medical oncology
Solange Peters, Lausanne, Switzerland

LuCE: the patient’s perspective
Cilia Linssen, Baarn, Netherlands

12:30 LUNCH & POSTER DISPLAY SESSION
See page 40 for details
13:10/ 14:20  INDUSTRY SATELLITE SYMPOSIUM
The (r)evolution of advanced Non-Small Cell Lung Cancer
See page 62 for details

13:10/ 14:20  INDUSTRY SATELLITE SYMPOSIUM
Maximizing treatment benefit for patients with ALK positive NSCLC
See page 62 for details

14:30/ 16:00  EDUCATIONAL SESSION
Focus on treatment complications and optimal management
Chairs: Maciej Krzakowski, Warsaw, Poland and Matthias Guckenberger, Würzburg, Germany

14:30  Surgery
Paul Van Schil, Edegem, Belgium

14:50  Radiation oncology
Dirk De Ruysscher, Leuven, Belgium

15:10  Late and chronic toxicity of chemotherapy
Glenwood D. Goss, Ottawa, ON, Canada

15:30  New toxicities of targeted agents
Silvia Novello, Orbassano, Italy

15:50  Questions and answers

14:30/ 16:00  EDUCATIONAL SESSION
ESMO, ASCO and NCCN: Common ground and differences - which one to follow?
Chairs: Paul Baas, Amsterdam, Netherlands and James Mulshine, Chicago, IL, US

14:30  Screening
James Mulshine, Chicago, IL, US

14:55  Early stage and locally advanced
Wilfried Eberhardt, Essen, Germany

15:20  Stage IV
Enriqueta Felip, Barcelona, Spain

15:45  Questions and answers

14:30/ 15:30  POSTER DISCUSSION 2
Chairs: Pasi Jänne, Boston, MA, US and Oliver Gautschi, Lucerne, Switzerland

27PD - Lung cancer detection with chest digital tomosynthesis: Results from the SOS Observational Study
Luca Bertolaccini, Cuneo, Italy

28PD - Measuring the population impact of introducing stereotactic ablative radiotherapy (SABR) for stage I NSCLC in Canada
Alexander Louie, Amsterdam, Netherlands
75PD - Efficacy by T categories of the postoperative adjuvant immunotherapy with Ubenimex (Bestatin○R) on survival in patients with stage I squamous-cell lung cancer: an exploratory analysis from a randomized phase III study

Masahiro Tsuboi, Yokohama, Japan

14:30 Discussant abstracts: 27PD, 28PD and 75PD

Oliver Gautschi, Lucerne, Switzerland

96PD - Clinical Activity, Safety and Subpopulation Response Analysis of Nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in Patients (pt) With Non-Small Cell Lung Cancer (NSCLC)

Julie Brahmer, Baltimore, MD, US

97PD - Nintedanib (BIBF 1120) + docetaxel as 2nd-line therapy in patients with stage IIIB/IV or recurrent NSCLC: Results of the Phase III, randomised, double-blind LUME-Lung 1 trial. (For the LUME-Lung 1 Study Group)

Martin Reck, Grosshansdorf, Germany

98PD - Exon 20 mutations of the Epidermal Growth Factor Receptor (EGFR) in Lung Adenocarcinomas: Clinicopathologic Factors and Response to Therapy

Jarushka Naidoo, New York, NY, US

99PD - High proportion of complete radiologic and metabolic response and prolonged progression-free survival after intercalated chemotherapy and erlotinib for advanced NSCLC with activating EGFR mutations

Matjaz Zwitter, Ljubljana, Slovenia

100PD - PGG β-glucan with carboplatin, paclitaxel and cetuximab for chemoimmunotherapy of advanced non-small cell lung cancer (NSCLC)

Parvis Sadjadian, Minden, Germany

14:50 Discussant abstracts: 96PD, 97PD, 98PD, 99PD and 100PD

Pasi Jänne, Boston, MA, US

15:10 General discussion

16:00 COFFEE BREAK

16:30/18:00 EDUCATIONAL SESSION

The potential of immunotherapy in NSCLC

Chairs: Johan Vansteenkiste, Leuven, Belgium and Julie Brahmer, Baltimore, MD, US

16:30 The biology of the immune system in lung cancer

David Carbone, Columbus, OH, US

16:50 New targets and vaccines (including biomarkers)

Johan Vansteenkiste, Leuven, Belgium

17:10 The evolution of immune checkpoint inhibitors

Roy Herbst, New Haven, CT, US
17:30 How to combine immunotherapy with standard approaches
**Martin Reck, Grosshansdorf, Germany**

17:50 Questions and answers

---

16:30/18:00 **EDUCATIONAL SESSION**

**ROOM C**

**Oligometastatic NSCLC**

Chairs: Rolf Lewensohn, Stockholm, Sweden and Gaetano Rocco, Naples, Italy

16:30 The definition of oligometastatic metastatic disease
**Christophe Dooms, Leuven, Belgium**

16:50 The changing role of radiotherapy
**Suresh Senan, Amsterdam, Netherlands**

17:10 The biology behind oligometastatic NSCLC
**Federico Cappuzzo, Livorno, Italy**

17:30 The changing role of surgery
**Eric Vallieres, Seattle, WA, US**

17:50Questions and answers

---

**Saturday, 29 March 2014**

**08:00/08:50 MULTIDISCIPLINARY INTERACTIVE SESSION**

**ROOM X**

**Neo-adjuvant chemotherapy vs chemoradiotherapy**

Chairs: Anne-Marie Dingemans, Maastricht, Netherlands and Miklos Pless, Winterthur, Switzerland

08:00 Chemotherapy
**Anne-Marie Dingemans, Maastricht, Netherlands**

08:15 Chemoradiotherapy
**Miklos Pless, Winterthur, Switzerland**

08:30 Discussion

---

**08:00/08:50 MULTIDISCIPLINARY INTERACTIVE SESSION**

**ROOM W**

**Bone metastasis in NSCLC**

Chairs: Vera Hirsh, Montreal, QC, Canada and Frederic Deschamps, Villejuif, France

08:00 Bisphosphonates and beyond
**Vera Hirsh, Montreal, QC, Canada**

08:15 Interventional treatments
**Frederic Deschamps, Villejuif, France**

08:30 Discussion

---

**09:00/09:30 KEYNOTE LECTURE**

**ROOM A&B**

**Molecular testing for clinical practice**

Chair: Rolf A. Stahel, Zurich, Switzerland and Rafal Dziadziuszko, Gdansk, Poland

09:00 **Speaker: Keith Kerr, Aberdeen, UK**
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:30</td>
<td>EDUCATIONAL SESSION</td>
<td>ROOM A&amp;B</td>
</tr>
<tr>
<td>09:45</td>
<td>Challenges in the treatment of early NSCLC: What is the standard, what are the challenges and what is the future? Chairs: Jan Van Meerbeeck, Edegem and Gaetano Rocco, Naples, Italy</td>
<td></td>
</tr>
<tr>
<td>09:30</td>
<td>Radiotherapy</td>
<td></td>
</tr>
<tr>
<td>09:30</td>
<td>Cecile Le Pechoux, Villejuif, France</td>
<td></td>
</tr>
<tr>
<td>09:55</td>
<td>Surgery</td>
<td></td>
</tr>
<tr>
<td>09:55</td>
<td>Gaetano Rocco, Naples, Italy</td>
<td></td>
</tr>
<tr>
<td>10:20</td>
<td>Systemic treatment</td>
<td></td>
</tr>
<tr>
<td>10:20</td>
<td>Lucio Crinò, S. Andrea, Italy</td>
<td></td>
</tr>
<tr>
<td>10:45</td>
<td>Questions and answers</td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>COFFEE BREAK</td>
<td>EXHIBITION</td>
</tr>
<tr>
<td>11:20</td>
<td>EDUCATIONAL SESSION</td>
<td>ROOM A&amp;B</td>
</tr>
<tr>
<td>11:20</td>
<td>Treatment choices of advanced NSCLC patients without driver mutations Chairs: Giorgio Scagliotti, Orbassano, Italy and Kostas Syrigos, Athens, Greece</td>
<td></td>
</tr>
<tr>
<td>11:20</td>
<td>Systemic treatment</td>
<td></td>
</tr>
<tr>
<td>11:20</td>
<td>Frances Shepherd, Toronto, ON, Canada</td>
<td></td>
</tr>
<tr>
<td>11:40</td>
<td>Angiogenesis</td>
<td></td>
</tr>
<tr>
<td>11:40</td>
<td>Alex A. Adjei, Buffalo, NY, US</td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td>Maintenance</td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td>Giorgio Scagliotti, Orbassano, Italy</td>
<td></td>
</tr>
<tr>
<td>12:20</td>
<td>Elderly and PS2 patients</td>
<td></td>
</tr>
<tr>
<td>12:20</td>
<td>Egbert Smit, Amsterdam, Netherlands</td>
<td></td>
</tr>
<tr>
<td>12:40</td>
<td>Questions and answers</td>
<td></td>
</tr>
<tr>
<td>12:50</td>
<td>CLOSING REMARKS</td>
<td>ROOM A&amp;B</td>
</tr>
<tr>
<td>13:00</td>
<td>Chairs: Enriqueta Felip, Barcelona, Spain and Rafal Dziadzieszko, Gdansk, Poland</td>
<td></td>
</tr>
</tbody>
</table>